Important Safety Information | NIOX VERO® User Manual (PDF)

For US Healthcare Professionals Only

For questions about coronavirus/COVID-19 and using NIOX VERO®, please visit the NIOX VERO Coronavirus/COVID-19 FAQ.

FeNO Recognition

FeNO-Guided Management is Recognized by the Following:

Professional Associations

ATS: American Thoracic Society3
www.thoracic.org

AAAAI: American Academy of Allergy Asthma & Immunology4 - www.aaaai.org

ACAAI: American College of Allergy, Asthma & Immunology4 - acaai.org

BTS: British Thoracic Society5
www.brit-thoracic.org.uk

GINA: Global Initiative for Asthma6
www.ginasthma.org

SIGN: Scottish Intercollegiate Guidelines Network5
www.sign.ac.uk

Governmental Agencies

AHRQ: Agency for Healthcare Research and Quality7 - www.ahrq.gov

NICE: National Institute for Clinical Excellence8
www.nice.org.uk

EPR-4: Expert Panel Working Group, National Asthma Education and Prevention Program Draft Update9
www.epr4workgroup.org

Patient Advocacy Groups

AAFA: Asthma and Allergy Foundation of America10 - www.aafa.org

Allergy & Asthma Network10
www.allergyasthmanetwork.org

References

References: 1. LaForce C, Brooks E, Herje N, Dorinsky P, Rickard K. Impact of exhaled nitric oxide measurements on treatment decisions in an asthma specialty clinic. Ann Allergy Asthma Immunol. 2014;113(6):619-623. 2. Hanania NA, Alpan, O, Hamilos, DL et al. Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy. Ann Intern Med. 2011;154:573-582. 3. Dweik RA, Boggs PB, Erzurum SC, et al; on behalf of the American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602-615. 4. American Academy of Allergy, Asthma, and Immunology and American College of Allergy, Asthma, and Immunology. AAAAI/ACAAI joint statement of support of the ATS clinical practice guideline: interpretation of exhaled nitric oxide for clinical applications. https://www.aaaai.org/Aaaai/media/MediaLibrary/PDF%20Documents/My%20Membership/FeNOJointStatement3-6-12.pdf. Accessed March 31, 2016. 5. British Thoracic Society. British guideline on the management of asthma: A national clinical guideline, 2016. Available at: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/. 6. Global Initiative for Asthma. Difficult-To-Treat & Severe Asthma in adolescent and adult patients: A GINA Pocket Guide For Health Professionals. https://ginasthma.org/wp-content/uploads/2018/11/GINA-SA-FINAL-wms.pdf. Accessed November 20, 2018. 7.Agency for Healthcare Research and Quality (ARHQ). The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management. https://effectivehealthcare.ahrq.gov/sites/default/files/pdf/cer-197-fractional-exhaled-nitricoxide_0.pdf. Accessed February 26, 2018. 8.  NICE guideline [NG80]: Asthma: diagnosis, monitoring and chronic asthma management. Published November 2017: https://www.nice.org.uk/guidance/ng80. 9. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Update on Selected Topics in Asthma Management: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. https://www.epr4workgroup.org/Asthma2020Guidelines/Shared%20Documents/Asthma-Guidelines-Report.pdf. Accessed February 18, 2020. 10. Data on file. Circassia Pharmaceuticals January 2019.